Skip to content

Add-on effect of Low-concentration atropine among children with poor myopia control by peripheral defocus glasses

Add-on effect of Low-concentration atropine among children with poor myopia control by peripheral defocus glasses: a randomized, placebo controlled, double-masked, clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091544
Enrollment
Unknown
Registered
2024-10-30
Start date
2025-06-16
Completion date
Unknown
Last updated
2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myopia

Interventions

Placebo Control:The intervention is to instill eyedrop (placebo) once nightly for 1 year.
0.01% atropine:The intervention is to instill eyedrop ( 0.01% atropine) once nightly for 1 year.
0.04% atropine:The intervention is to instill eyedrop ( 0.04% atropine) once nightly for 1 year.

Sponsors

Eye Hospital Affiliated to Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 10 Years

Inclusion criteria

Inclusion criteria: 1. Wearing a certain type of peripheral defocus design frame lens in the past 6 to 12 months, during which the growth rate of the binocular axis is >=0.20mm/year (calculation formula: the difference between the axial length of the two visits/the number of days between the two visits*365 days/year); 2. Refractive state (computerized refraction after cycloplegia): binocular equivalent spherical power between -1.00D (inclusive) ~ -6.00D (exclusive), anisometropic <=1.50D, astigmatism <=1.50D in either eye; 3. Age 6 (inclusive) ~ 10 (inclusive) years old 4. Both the subject and the guardian signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Suffering from strabismus, amblyopia or other eye diseases; 2. Intraocular pressure > 21mmHg in either eye, or intraocular pressure difference >5mmHg in both eyes; 3. Use atropine eye drops while wearing peripheral defocus design frame lenses; 4. Allergy or intolerance to atropine; 5. Inability to participate in regular follow-up visits; 6. The rest of the conditions determined by the investigator to be unsuitable for participation in the study.

Design outcomes

Primary

MeasureTime frame
1-year change in axial length;

Secondary

MeasureTime frame
1-year change in cycloplegic spherical equivalent refraction;The proportion of subjects whose axial length change within 1 year is within the ideal control range (<0.20 mm/year).;The proportion of subjects whose myopic refractive progression within 1 year is within the ideal control range (<0.50 D/year).;

Countries

China

Contacts

Public ContactMao, Xinjie

Eye Hospital Affiliated to Wenzhou Medical University

mxj@mail.eye.ac.cn+86 137 0588 0472

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026